Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
J Am Coll Cardiol. 2013 Nov 12;62(20):1857-65. doi: 10.1016/j.jacc.2013.07.020. Epub 2013 Jul 31.
This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).
AF is a precipitating factor for clinical deterioration of HFPEF.
Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%). AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated. LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.
During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively. Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54). No major complications occurred during follow-up. Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively). LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.
Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF. However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.
本研究旨在探讨导管消融治疗射血分数保留的心力衰竭伴心房颤动(HFPEF)患者的疗效和安全性。
AF 是 HFPEF 临床恶化的诱发因素。
对 74 例射血分数>50%的代偿性 HFPEF 患者进行 AF 导管消融。研究了导管消融后的 AF 无复发率和维持窦律的相关因素。在基线和消融后 12 个月通过超声心动图评估左心室应变和应变率。
在 34±16 个月的随访期间,单和多程序无药物成功率分别为 27%(n=20)和 45%(n=33),多程序和药物辅助成功率为 73%(n=54)。随访期间无重大并发症发生。多变量 Cox 回归分析显示,AF 类型(除长程持续性 AF 外)和无高血压与维持窦律独立相关(风险比[HR]:1.81,95%置信区间[CI]:1.03 至 3.17,p=0.04;HR:0.49,95%CI:0.24 至 0.96,p=0.04)。仅在随访时维持窦律的患者,LV 收缩指标(LV 射血分数、LV 收缩期应变/应变率)和舒张指标(E/E',早期二尖瓣血流传播速度与 LV 应变率之比)均有改善。
我们的结果表明,在 HFPEF 患者中,重复程序和药物联合治疗可有效、安全地治疗 AF。然而,本研究为单臂分析,因此需要更大规模的随机对照研究来验证 AF 消融在这一人群中的获益。